Device Trial Radar · NCT02134379
Dynamic Thoracic Impedance as a Marker for Heart Failure Decompensation
Last checked: Nov 19, 2026Latest source record: Apr 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Apr 2014
Primary completion
Jan 2016
Study completion Jan 2016
Sponsor
- Lead sponsor
- Charles Porter, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medtronic
- First posted
- May 9, 2014
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot study proposes to perform measurements of approved thoracic impedance technology that will help answer questions in patients with decompensated heart failure.
Conditions
- Heart Failure; With Decompensation
Interventions
Medtronic ICDs, CRT-Ds, and CRT-PsDevice
Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from sitting to supine to standing in thoracic impedanceTime frame: Baseline, 30 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Kansas Medical Center
Kansas City, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.